Literature DB >> 33949001

Relationship between plasma rabbit anti-thymocyte globulin concentration and immunosuppressive therapy response in patients with severe aplastic anemia.

Atsushi Narita1, Hideki Muramatsu1, Daisuke Ichikawa1, Motoharu Hamada1, Eri Nishikawa1, Kyogo Suzuki1, Nozomu Kawashima1, Yusuke Okuno1, Nobuhiro Nishio1, Asahito Hama1,2, Hirohito Yamazaki3, Shinji Nakao4, Seiji Kojima1, Yoshiyuki Takahashi1.   

Abstract

OBJECTIVES: Patients with acquired aplastic anemia (AA) without HLA-matched sibling donors or aged >40 years receive immunosuppressive therapy (IST) with anti-thymocyte globulin (ATG). We investigated the relationship between plasma rabbit ATG (r-ATG) concentration and IST response.
METHODS: From May 2012 to October 2017, 81 patients with severe AA who required initial IST were included. A 1:1 block randomization was employed for 2.5 and 3.5 mg/kg doses of r-ATG.
RESULTS: No significant difference in response rates was observed between the 2.5 and 3.5 mg/kg groups (63% vs. 58%, P = .894). Median r-ATG concentrations on days 14 and 28 after IST were 15.2 (0.0-97.7) and 1.8 (0.0-74.9 µg/mL), respectively. According to r-ATG concentration, response rates were significantly higher in the group with higher r-ATG concentration than in those with lower r-ATG concentration (day 14, 88% vs. 52%; P = .006 and day 28, 79% vs. 46%; P = .005). In multivariate analysis, higher r-ATG concentrations at day 28 were independent predictors of favorable response to IST at 6 months (odds ratio, 0.29; 95% confidence interval, 0.09-0.93; P = .037).
CONCLUSIONS: The present data indicate that higher r-ATG concentration at day 28 resulted in improved IST response.
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  aplastic anemia; immunosuppressive therapy; plasma concentration; rabbit ATG

Mesh:

Substances:

Year:  2021        PMID: 33949001     DOI: 10.1111/ejh.13644

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  2 in total

1.  First-line immunosuppressive therapy with rATG and CsA for severe aplastic anemia: 15 years' experience.

Authors:  Jing Hu; Li Zhang; Xin Zhao; Xu Liu; Liping Jing; Kang Zhou; Yuan Li; Yang Li; Jianping Li; Lei Ye; Guangxin Peng; Huihui Fan; Wenrui Yang; Yang Yang; Youzhen Xiong; Lin Song; Fengkui Zhang
Journal:  Ann Hematol       Date:  2022-09-24       Impact factor: 4.030

2.  Apolipoprotein-A is a potential prognostic biomarker for severe aplastic anemia patients treated with ATG-based immunosuppressive therapy: a single-center retrospective study.

Authors:  Qi Liu; Huijie Dong; Yuzhu Li; Yingying Shen; Yilei Hong; Ying Chen; Shan Liu; Xiaolian Wu; Wenbin Liu; Huijin Hu; Yuechao Zhao; Shenyun Lin; Yiping Shen; Yuhong Zhou; Baodong Ye; Dijiong Wu
Journal:  Lipids Health Dis       Date:  2022-10-04       Impact factor: 4.315

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.